Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Lentiviral vectors are used as a means to deliver foreign genetic material into another cell. These vectors are developed from lentivirus, a type of retrovirus, which are characterized by their long incubation period and can infect both dividing and non-dividing cells. The lentiviral vectors are derived from human immunodeficiency virus (HIV) and hence, these vectors are highly efficient vehicles for in vivo gene delivery for gene therapies.

Market players are focusing on robust production of high quality lentiviral vectors through various inorganic growth strategies such as collaborations and agreements, which is expected to boost the global lentiviral vectors market growth over the forecast period. For instance, in June 2019, Servier Laboratories, an international pharmaceutical company, collaborated with Yposkesi, Inc, a contract development and manufacturing organization (CDMO), for the production of high quality lentiviral vectors.

The global lentiviral vectors market is estimated to be valued at US$ 176.9 million in 2020 and is expected to exhibit a CAGR of 18.3% over the forecast period (2020-2027).

Figure 1. Global Lentiviral Vectors Market Share (%) in Terms of Value, By Region, 2019

Lentiviral Vectors  | Coherent Market Insights

Increasing research and development activities by market players is expected to propel the market growth over the forecast period

Various manufacturers are engaged in research and development activities for novel lentiviral gene therapies, which is expected to drive growth of the global lentiviral vectors market. For instance, on May 14, 2020, AVROBIO, Inc., a clinical-stage gene therapy company, presented pre-clinical data AVR-RD-03 for Pompe disease. The study showcased the potential of lentiviral gene therapy approach for Pompe disease manifestations in the muscle and central nervous system (CNS).  

request-sample

Lentiviral Vectors Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2019: US$ 176.9 Mn
Historical Data for: 2016 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 18.3% 2027 Value Projection: US$ 573.6 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Product Type: 1st-generation, 2nd-generation, 3rd-generation.
  • By Indication: HIV, β-thalassemia, X-linked Adrenoleukodystrophy, Metachromatic Leukodystrophy, Wiskott-Aldrich Syndrome.
  • By End User: Hospitals, Clinics, Research Institutes.
Companies covered:

Thermo Fisher Scientific Sirion-Biotech GmbH, Vigene Biosciences, OriGene Technologies, Inc., SignaGen Laboratories, Sino Biological Inc., Takara Bio Inc., Cell Biolabs, Inc., GenTarget Inc., GENEMEDI, and bluebird bio, Inc.

Growth Drivers:
  • Increasing research and development activities by market players
  • Increasing agreements and collaborations
Restraints & Challenges:
  • Potential generation of replication competent virus
  • The possibility of oncogenesis through insertional mutagenesis

Increasing agreements and collaborations by market players is expected to drive the market growth over the forecast period

Key players are focusing on various inorganic growth strategies such as agreements and collaborations, which is expected to growth of the lentiviral vectors market over the forecast period. For instance, in May 2017, bluebird bio, Inc. entered into a license agreement with Novartis Pharma AG. Under this agreement, Novartis will non-exclusively license certain bluebird patent rights related to lentiviral vector technology to develop and commercialize therapies for oncology.

Figure 2. Global Lentiviral Vectors Market Value (US$ Mn), 2016 – 2027

Lentiviral Vectors  | Coherent Market Insights

Global Lentiviral Vectors Market – Impact of Coronavirus (Covid-19) Pandemic

The U.S. Food and Drug Administration (FDA) released guidelines on conducting clinical trials of medical products during the COVID-19 public health emergency in March 2020. The guidelines were further updated on July 02, 2020.

The guidelines issued by the U.S. Food and Drug Administration (FDA) include general considerations to assist sponsors and researchers, which ensure the safety of trial participants, compliance with good clinical practice (GCP), and minimize the risks of trial integrity during the COVID-19 public health emergency.

The appendix of the guidelines has also provided answers to some general questions, which the U.S. Food and Drug Administration (FDA) had received from various sponsors and researchers about conducting clinical trials during the COVID-19 public health emergency.  

Lentiviral Vectors Market Restraint

The major factors restraining growth of the lentiviral vectors market is potential generation of replication competent virus and the possibility of oncogenesis through insertional mutagenesis.

Key Players

Major players operating in the global lentiviral vectors market include Thermo Fisher Scientific Sirion-Biotech GmbH, Vigene Biosciences, OriGene Technologies, Inc., SignaGen Laboratories, Sino Biological Inc., Takara Bio Inc., Cell Biolabs, Inc., GenTarget Inc., GENEMEDI, and bluebird bio, Inc.

Lentiviral vectors are potential gene transfer vehicles used in both research and gene therapy applications. Lentiviral vectors have the capacity to stably express a gene of interest in non-dividing and diving cells, which makes them efficient vehicles for gene transfer. Lentiviral vectors are used for the treatment of various rare genetic disorders such as β-thalassemia, X-linked Adrenoleukodystrophy, X-linked severe combined immunodeficiency (SCID-X1) and Metachromatic Leukodystrophy. Moreover, various market players are focusing on increasing their research and development activities for gene therapies including lentiviral vectors, in order to enhance their product portfolio, which is expected to drive growth of the global lentiviral vectors market over the forecast period. For instance, in May, 2019, Avrobio Inc. initiated a phase I/II trial for lentiviral vector gene therapy including AVR-RD-02 for patients with type 1 Gaucher disease.

Market Dynamics

Market players are focusing on adopting various inorganic growth strategies such as agreements, acquisitions, partnerships, and collaborations, in order to strengthen their market presence, which is expected to drive growth of the global lentiviral vectors market over the forecast period. For instance, on April 07, 2020, SIRION Biotech GmbH announced that it entered into an agreement with Beam Therapeutics, a biotechnology company, which is focusing on the use of CRISPR technology for the development of advanced genetic medicines. Under this agreement, SIRION Biotech GmbH provided the non-exclusive access of its proprietary lentiviral transduction enhancer LentiBOOST, to Beam Therapeutics for clinical development and commercialization of CAR-T programs.  

Key features of the study:

  • This report provides in-depth analysis of the global lentiviral vectors market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2020–2027), considering 2019 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global lentiviral vectors market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Thermo Fisher Scientific, Sirion-Biotech GmbH, Vigene Biosciences, OriGene Technologies, Inc., SignaGen Laboratories, Sino Biological Inc., Takara Bio Inc., Cell Biolabs, Inc., GenTarget Inc., GENEMEDI, and bluebird bio, Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global lentiviral vectors market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global lentiviral vectors market

Detailed Segmentation:

  • Global Lentiviral Vectors Market, By Product Type:
    • 1st-generation
    • 2nd-generation
    • 3rd-generation
  • Global Lentiviral Vectors Market, By Indication:
    • HIV  
    • β-thalassemia   
    • X-linked Adrenoleukodystrophy 
    • Metachromatic Leukodystrophy 
    • Wiskott-Aldrich Syndrome
  • Global Lentiviral Vectors Market, By End User:
    • Hospitals
    • Clinics
    • Research Institutes
  • Global Lentiviral Vectors Market, By Region:
    • North America
      • By Product Type:
        • 1st-generation
        • 2nd-generation
        • 3rd-generation
      • By Indication
        • HIV 
        • β-thalassemia  
        • X-linked Adrenoleukodystrophy 
        • Metachromatic Leukodystrophy 
        • Wiskott-Aldrich Syndrome
      • By End User:
        • Hospitals
        • Clinics
        • Research Institutes
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Product Type:
        • 1st-generation
        • 2nd-generation
        • 3rd-generation
      • By Indication
        • HIV 
        • β-thalassemia  
        • X-linked Adrenoleukodystrophy 
        • Metachromatic Leukodystrophy 
        • Wiskott-Aldrich Syndrome
      • By End User:
        • Hospitals
        • Clinics
        • Research Institutes
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Product Type:
        • 1st-generation
        • 2nd-generation
        • 3rd-generation
      • By Indication
        • HIV 
        • β-thalassemia  
        • X-linked Adrenoleukodystrophy 
        • Metachromatic Leukodystrophy 
        • Wiskott-Aldrich Syndrome
      • By End User:
        • Hospitals
        • Clinics
        • Research Institutes
      • By Country:
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Product Type:
        • 1st-generation
        • 2nd-generation
        • 3rd-generation
      • By Indication
        • HIV 
        • β-thalassemia  
        • X-linked Adrenoleukodystrophy 
        • Metachromatic Leukodystrophy 
        • Wiskott-Aldrich Syndrome
      • By End User:
        • Hospitals
        • Clinics
        • Research Institutes
      • By Country:
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Product Type:
        • 1st-generation
        • 2nd-generation
        • 3rd-generation
      • By Indication
        • HIV 
        • β-thalassemia  
        • X-linked Adrenoleukodystrophy 
        • Metachromatic Leukodystrophy 
        • Wiskott-Aldrich Syndrome
      • By End User:
        • Hospitals
        • Clinics
        • Research Institutes
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Product Type:
        • 1st-generation
        • 2nd-generation
        • 3rd-generation
      • By Indication
        • HIV 
        • β-thalassemia  
        • X-linked Adrenoleukodystrophy 
        • Metachromatic Leukodystrophy 
        • Wiskott-Aldrich Syndrome
      • By End User:
        • Hospitals
        • Clinics
        • Research Institutes
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Thermo Fisher Scientific*
      • Company Overview
      • Material Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • Sirion-Biotech GmbH
    • Vigene Biosciences
    • OriGene Technologies, Inc.
    • SignaGen Laboratories
    • Sino Biological Inc.
    • Takara Bio Inc.
    • Cell Biolabs, Inc.
    • GenTarget Inc.
    • GENEMEDI
    • bluebird bio, Inc.

“*” marked represents similar segmentation in other categories in the respective section.    

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Product Type
      • Market Snippet, By Indication
      • Market Snippet, By End User
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Key Developments
    • PEST Analysis
  4. Global Lentiviral Vectors Market – Impact of Coronavirus (Covid-19) Pandemic
    • Pre COVID-19 Market Scenario
    • Post COVID-19 Market Scenario
    • Overall Impact on Healthcare Market
    • Clinical Trial Analysis
  5. Global Lentiviral Vectors Market, By Product Type, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • 1st-generation
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • 2nd-generation
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • 3rd-generation
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  6. Global Lentiviral Vectors Market, By Indication, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • HIV  
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • β-thalassemia   
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • X-linked Adrenoleukodystrophy  
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Metachromatic Leukodystrophy  
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Wiskott-Aldrich Syndrome   
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  7. Global Lentiviral Vectors Market, By End User, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Hospitals
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Clinics
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Research Institutes
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  8. Global Lentiviral Vectors Market, By Region, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, By Region, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017–2027
    • North America
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Indication, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Indication, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Indication, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Indication, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Indication, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Indication, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country/Region, 2016 – 2027, (US$ Mn)
        • South Africa
        • Central Africa
        • North Africa
  9. Competitive Landscape
    • Heat Map Analysis
    • Market Share Analysis
      • Thermo Fisher Scientific
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Sirion-Biotech GmbH
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Vigene Biosciences
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • OriGene Technologies, Inc.
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • SignaGen Laboratories
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Sino Biological Inc.
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Takara Bio Inc
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Cell Biolabs, Inc.
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • GenTarget Inc.
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • GENEMEDI
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • bluebird bio, Inc.
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
    • Analyst Views
  10. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 54 market data tables and 48 figures on "Lentiviral Vectors Market” - Global forecast to 2027

Frequently Asked Questions

The global lentiviral vectors market size is estimated to surpass US$ 573.6 million by 2027.
The global lentiviral vectors market is expected to register a CAGR of 18.3% during the forecast period (2020-2027).
The increasing research and development activities and increasing mergers and collaborations by market players are driving the global lentiviral vectors market growth.
The HIV segment is expected to hold major market share in 2020, owing to the increasing prevalence of HIV.
Major factors hampering growth of the market are potential generation of replication competent virus and the possibility of oncogenesis through insertional mutagenesis.
Major players operating in the global lentiviral vectors market include Thermo Fisher Scientific Sirion-Biotech GmbH, Vigene Biosciences, OriGene Technologies, Inc., SignaGen Laboratories, Sino Biological Inc., Takara Bio Inc., Cell Biolabs, Inc., GenTarget Inc., GENEMEDI, and bluebird bio, Inc.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner